Thermo Fisher Scientific Inc. has emerged as the leading bidder to buy biopharmaceutical data provider CorEvitas from Audax Group, the middle-market private equity firm, according to people familiar with the matter.
Thermo Fisher has submitted the strongest bid in a sales process that could value CorEvitas at about $1 billion, said the people, who asked to not be identified because the details are private. An agreement could be announced within weeks, the people said. Other suitors are in the mix, nothing has been finalized and Audax could opt to hold onto the business, the people added.
Audax has been working with advisers to explore options including a potential sale for CorEvitas and the portfolio company had drawn interest from other pharma services companies and financial sponsors, the people said.
Read the full story on Bloomberg here.